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CBackground: Costs and benefits of emerging prostate cancer treatments
for young men (age  65 years) in the United States are not well under-
stood.Wecomparedutilization, clinical outcomes, andcostsbetween two
types of radical prostatectomy (RP)—minimally invasive prostatectomy
(MIRP) and retropubic prostatectomy (RRP)—among young patients.
Methods: We extracted from LifeLink Health Plan Claims Database, a
commercial claims database, information on 10,669 patients receiving ei-
therMIRP or RRP between 2003 and 2007. In unadjusted analyses,weused
chi-square tests to compare clinical outcomes and nonparametric boot-
strapping method to compare costs between the MIRP and RRP groups.
We applied logistic, Cox proportional hazard, and extended estimation
equationmethods to examine the association between surgical modality
and perioperative complications, anastomotic stricture, and costs while
controlling for age, comorbidity, and health plan characteristics.
Results: The percentage of prostatectomies performed as MIRP in-
creased from 5.7% in 2003 to 50.3% in 2007. Patients withmore comorbid- O
o rep
ital M
al So
doi:10.1016/j.jval.2011.10.008ty were more likely to undergo RRP than MIRP. Compared with the RRP
roup, theMIRP grouphad a significantly lower rate of perioperative com-
lications (23.0% vs. 30.4%; P  0.001) and a lesser tendency for anasto-
otic strictures (hazard ratio 0.42; 95% CI 0.35–0.50) within the first post-
perative year but had higher hospitalization costs ($19,998 vs. $18,424;
 0.001) despite shorter hospitalizations (1.7 days vs. 3.1 days; P 0.001).
imilar findings were reported in the subgroup analysis of patients with
omorbidity score 0. Conclusion: MIRP among nonelderly patients in-
reased substantially over time. MIRPwas found to have fewer complica-
ions. Lower costs of complications appeared to have offset higher hospi-
alization costs of MIRP.
eywords: cancer, claims databases, cost analysis, managed care, min-
mally invasive surgeries.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The decision of a patient with prostate cancer to pursue radical
prostatectomy (RP), radiation therapy, or active surveillance con-
stitutes a complex interplay of the preferences and risk tolerance
of the patient and his physician. The treatment strategy is further
complicated by the paucity of scientific information with which to
compare a growing list of emerging surgical options. Better treat-
ment guidelines have been hampered by a lack of randomized
clinical trials or incomplete prospective comparative trials. Non-
standardized metrics of treatment response and quality-of-life
outcomes across studies have further muddled the decision-mak-
ing process. This uncertainty among providers and consumers has
catalyzed marked variability in prostate cancer treatments across
the country.
Given the lack of randomized controlled trials to provide
definitive answers for this most commonly diagnosed cancer in
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Published by Elsevier Inc.males [1], costs associated with various treatment options are
likely to become increasingly important in the decision-making
process. More than 75,000 prostatectomies are performed annu-
ally in the United States [2]. The estimated cost for the first 6
months of prostate cancer treatment is in the range of $13,000
to $17,000 (2002 US dollars) for elderly patients treated with RP
[2,3]. Since that time, a number of emerging technologies have
been introduced. Minimally invasive RP (MIRP), such as robotic-
assisted or standard laparoscopic RP, has become one of the
most popular forms of primary prostate cancer therapy.
Between 2003 and 2005, the proportion of Medicare benefi-
ciaries with newly diagnosed prostate cancer who underwent
MIRP increased from 12.2% to 31.4% among those who received
RP whereas patients undergoing retropubic RP (RRP) declined
from 82% to 66.1% [4]. A similar trend has also been reported in
studies including prostate cancer patients of all ages [5,6]. No
study, however, has focused exclusively on patients younger
than 65 years. This age group is of special importance, as an
ort.
edicine, Department of Medicine, University of Chicago, 5841 S.
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368 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 6 7 – 3 7 5earlier study showed that despite a decline in RP among elderly
patients, surgical treatment continued to increase among
younger patients [7]. In addition, no population-based study has
explored the impact of MIRP on the cost of prostate cancer care.
Theobjectives of this study are: 1) to understand theutilizationpat-
ternsof the twomost commonlyusedsurgical approaches toRP—MIRP
and RRP—from 2003 to 2007 among a cohort of young men (age  65
years) with prostate cancer and enrolled inmanaged care plans; and 2)
to compare the differences in outcomes and costs between patients
treatedwithMIRP and thosewith RRP.
Methods
Study population and identification of RP modalities
Byusing theLifeLinkHealthPlanClaimsDatabase, aproprietary claims
data, we identifiedmen 18 years and older and younger than 65 years
whounderwentRP from2003 to 2007. Thedatabase represents approx-
imately 55 million individuals frommore than 95managed care plans
throughout the United States and contains information on enrollment
Table 1 – ICD-9 and CPT codes to identify perioperative com
Complication ICD-9 diagnosis codes
Cardiac 410.X, 402.01, 402.11, 402.91, 428.X,
427.5, 997.1
Respiratory 518.0, 514, 518.4, 466.X, 480.X, 481,
482.X, 483.X, 485, 486, 518.5,
518.81, 518.82, 799.1, 997.3
Vascular 415.1, 451.1X, 451.2, 451.81, 451.9,
453.8, 453.9, 997.2, 999.2, 444.22,
444.81, 433.X, 434.X, 436, 437.X
Wound or bleeding 567.X, 998.3, 998.5X, 998.6 54.6
Genitourinary 595.89, 590.1X, 590.2, 590.8X, 590.9,
591, 997.5, 596.1, 596.2, 596.6,
593.3, 593.4, 593.5, 593.81, 593.82
55.0
9
5
Miscellaneous medical 584.X, 586, 785.5X, 995.0, 995.4,
998.0, 999.4, 999.5, 999.6, 999.7,
999.8, 457.8, 560.1, 560.8X, 560.9,
997.4, 353.0, 354.2, 723.4, 955.1,
955.3, 955.7, 955.8, 955.9, 593.4,
531.1, 531.2, 531.3, 531.4, 531.5,
531.6, 531.9, 532.1, 532.2, 532.3,
532.4, 532.5, 532.6, 532.9, 533.1,
533.2, 533.3, 533.4, 533.5, 533.6,
533.9, 782.4, 573.8
Miscellaneous surgical 599.1, 596.1, 596.2, 596.6, 565.1,
569.3, 569.83, 569.4, 569.4X,
998.1X, 998.83, 998.9, 998.2,
998.4, 998.7, 604.0, E870.0,
E870.4, E870.7, E870.8, E870.9,
E871.0, E873.0, E876.0, 956.0,
956.1, 956.4, 956.5, 956.8, 956.9,
902.50, 902.51, 902.52, 902.53,
902.54, 902.59
46.0
4
Anastomotic stricture 596.0, 598.0, 598.1, 598.2, 598.8,
598.9
57.0
5
5
CPT, common procedural terminology; HCPCS, healthcare common p
NA, not applicable.records and onmedical and prescription drug claims. All claims datacan be linked to enrollment records via de-identified person
identifiers. The institutional review board of the University of
Texas MD Anderson Cancer Center exempted this study for ap-
proval.
Weclassifiedpatients intodifferentRPgroupsbyusingCurrent Pro-
cedural Terminology (CPT) codes: patients with prostate cancer with
CPT codes 55840, 55842, and 55845 were classified as the RRP group,
whereas thosewithCPTcode55866wereclassifiedas theMIRPgroup. It
should be noted that the CPT code for MIRP did not differentiate be-
tween laparoscopic and robotic RPs, and thus our datawould not allow
further stratificationof theMIRPprocedures. All patientswere required
to be continuously enrolled in the same health plan for at least 9
months,covering6monthsbeforeRP(forcalculatingcomorbidityscore)
and3months afterward (for trackingperioperative complications). The
selectionofa3-monthfollow-upperiodwasto facilitatecomparisonsof
perioperative complicationswith apublished studyusing theMedicare
data to compareMIRP and RRP among the elderly patients [4].
Outcome measures
We compared perioperative complications, anastomotic stric-
ations and stricture from claims.
D-9 procedure codes CPT/HCPCS codes
NA NA
NA NA
NA NA
91, 54.0, 54.19, 59.19 26990, 45020, 49060, 51080
03, 55.12, 55.93, 55.94, 59.93,
97.62, 56.1, 56.41, 56.74, 56.75,
56.84, 56.86, 56.89, 56.91
50040, 50120, 50125, 50395, 50398,
50605, 52290, 52332, 52334,
50600, 50700, 50715, 50760,
50770, 50780, 50782, 50783,
50785, 50800, 50810, 50815,
50820, 50825, 50840, 50900,
50940
NA NA
04, 46.10, 46.11, 46.14, 48.4X,
8.6X, 48.7X, 48.9X
X (except 57.11), 57.2X, 57.92,
7.4X, 57.85, 57.91, 58.0, 58.1,
58.44, 58.5
51010, 51040, 52510, 52281, 52283,
53600, 53601, 53605, 53620,
53621, 53640, 51800, 51820,
52275, 52276, 52310, 52500,
52620, 52640, 53000, 53010,
53020, 53400, 53405, 53410,
53415, 35420, 53425
ural coding system; ICD-9 International Classification of Diseases 9;plic
IC
1, 54.
2, 55.
7.61,
6.81,
3, 46.
8.5, 4
, 57.1
8.6, 5
8.3X,
rocedtures, and length of stays between patients in the MIRP and RRP
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cardiac, respiratory, or vascular events, wounds or bleeding, other
genitourinary conditions, and miscellaneous medical or surgical
events. Wemeasured the occurrence of strictures within 1 year of
the surgery because clinicians in our research team suggested that
a 90-day interval would be too short to capture this event. We
identified the above conditions and events by using the relevant
International Classification of Diseases 9 (ICD-9) or CPT codes from
inpatient and outpatient claims; these codes were based on previ-
ously published studies [4], with minor modifications to reflect
recent changes in coding. Specific codes used to identify each clin-
ical outcome from claims are summarized in Table 1.
Cost measures
The LifeLink Health Plan Claims Database collected three financial
variables: CHARGE, PAID, and ALLOWED. CHARGE is the amount
that was billed to a health plan, PAID is the amount actually paid
by the plan for a service, and ALLOWED is the amount the plan
allows for a specific service and includes the paid amount plus any
cosharing (e.g., copay) from the patients. Our cost measure was
based on ALLOWED, as this variable was considered most closely
reflecting the burden of illness and thus recommended by the data
vendor [8]. We compared costs between the MIRP and RRP groups
Table 2 – Patient characteristics, 2003–2007.
Characteristics Tota
Number of patients 10,66
Age (y) 57.44 (SD
Age group (y)
18–50 877 (8%
51–55 2359 (22
56–60 4260 (40
61–64 3173 (30
Payer type
Commercial 10060 (94
Medicaid 42 (0.4
Medicare risk 23 (0.2
Self-insured 368 (3.%
Medicare gap 8 (0.1
Missing/unknown 168 (2%
Health plan type
Consumer-directed health care 111 (1%
HMO 2581 (24
Indemnity 601 (6%
Point of service 5463 (51
PPO 1710 (16
Missing/unknown 203 (2)
Comorbidity score
0 8636 (81
1 1435 (13
2 597 (6%
Use of adjuvant radiation within 6 mo of surgery
Yes 38 (4%
No 10271 (96
Year
2003 1443 (14
2004 2208 (21
2005 2465 (23
2006 2709 (25
2007, first 9 mo 1844 (17
MIRP, minimally invasive radical prostatectomy; PPO, preferred prov
* P value from t test.
† P value from Pearson’s chi-square test.at three time intervals, costs associated with the hospitalizationfor RP, and cumulative costs within the first 3 and 6 months after
surgery, as well as costs of perioperative complications. The deci-
sion to extend our cost analysis to 6 months after surgery was
driven by an observation from our preliminary analysis that the
median time to stricture was beyond 3 months; therefore, a cost
analysis limited to a 3-month follow-up period would grossly un-
derestimate the cost impact of stricture. All cost estimates were
normalized to 2010 US dollars by using the medical care compo-
nent of the consumer price index.
Analysis
Statistical analyses included unadjusted and adjusted analyses. In
the unadjusted analyses, we compared the clinical outcomes and
costs between the MIRP and RRP groups by using Pearson chi-
square tests and nonparametric biased corrected and accelerated
bootstrapping method, respectively [9,10]. The nonparametric
bootstrapping method is an accepted approach to calculate confi-
dence intervals (CIs) for highly skewed data, such as medical cost
data [9]. The 3- and 6-month costs included costs of managing
complications and secondary interventions. The cost of hospital-
ization included costs incurred only during the admission for the
prostatic surgical procedure. For anastomotic stricture, we ob-
RRP MIRP P value
7,525 3,144
57.40 (SD 4.6) 57.52 (SD 4.7) 0.206*
615 (8%) 262 (8%) 0.126†
1667 (22%) 692 (22%)
3051 (41%) 1209 (39%)
2192 (29%) 981 (31%)
7034 (93%) 3026 (96%) 0.001†
33 (0.4%) 9 (0.3%)
18 (0.2%) 5 (0.2%)
282 (4%) 86 (3%)
7 (0.1%) 1 (0.03%)
151 (2%) 17 (0.5%)
59 (1%) 52 (2%) 0.001†
1868 (25%) 713 (23%)
440 (6%) 161 (5%)
3811 (50%) 1652 (52%)
1195 (16%) 515 (16%)
152 (2%) 51 (2%)
5968 (79%) 2668 (85%) 0.001†
1027 (14%) 409 (13%)
530 (7%) 67 (2%)
328 (4%) 70 (2%) 0.001†
7197 (96%) 3074 (98%)
1361 (18%) 82 (3%) 0.001†
1885 (25%) 323 (10%)
1802 (24%) 663 (21%)
1560 (21%) 1149 (37%)
917 (12%) 927 (30%)
rganization; RRP, retropubic radical prostatectomy.l
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370 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 6 7 – 3 7 5vival curve and tested the difference in the overall survival distri-
bution between the two groups by using the log-rank test.
In the adjusted analyses, we employed logistic regressions to
examine factors associated with the utilization of MIRP and to
ascertain the association between MIRP and each type of peri-
operative complication; we reported the results in odds ratios
(ORs) and associated 95% CIs. We applied a Cox proportional
hazard model to compare the time to a stricture event between
groups and reported the results in hazard ratios and 95% CIs. In
this model, “time” was defined as days from the date of RP to the
first appearance of stricture or the date of censoring. The data
could be censored either because of reaching the end of our
1-year observational period for stricture or from loss of fol-
low-up due to disenrollment of insurance after 3 months but
within 1 year of surgery. To determine whether the use of pro-
portional hazard model was appropriate, we tested the Cox pro-
portionality assumption by using the score test based on scaled
Schoenfeld residuals [11]. We analyzed the cost data by using
the extended estimation equation method; this method is a re-
cently developed econometric method to analyze the highly
skewed medical cost data [12].
Covariates in the multivariate analyses included age, payer
ype, health plan type, comorbidity score, and time trend. We
ategorized age in four categories—18 to 50, 51 to 55, 56 to 60, 61
o 64—and dichotomized payer type as commercial versus non-
ommercial plans. The type of health plan included indemnity
lan, HMO, preferred provider organization, point of service,
nd other plans. A comorbidity score was constructed for each
atient by using Klabunde’s algorithm [13]. This algorithm cal-
culated a modified Charlson comorbidity score [14] by using
data from inpatient and outpatient claims before the date of
cancer diagnosis. To improve specificity, this algorithm in-
cluded diagnosis codes from outpatient claims only if they ap-
peared more than once either in claims that were at least 30
days apart or in inpatient claim. Patients with comorbidity score
0 were considered the “healthy” cohort, whereas those with
Table 3 – Factors associated with the utilization of MIRP fro
Factor
Adjusted
Age group (reference groups 18–50 y)
51–55 1.00
56–60 0.95
61–64 0.92
Payer type (noncommercial payers)
Commerical 1.32
Plan types (reference group: indemnity plan)
HMO 1.40
Point of service 1.38
PPO 1.42
Other plans 1.73
Comorbidity (reference group: score  0)
Score 1 0.88
Score 2 0.27
Adjuvant radiation therapy within 6 mo of surgery
Yes vs. No 0.56
Time trend (reference group: year  2003)
2004 2.83
2005 6.08
2006 12.24
2007, first 9 mo 16.91
Pseudo R2
CI, confidence interval; MIRP, minimally invasive radical prostatectocomorbidity scores 1 and 2 or higher were patients with mildand moderate to severe health problems. Time trend was cap-
tured by a list of dichotomous variables for each calendar year
(2003–2007) to control for changes over time. In analyses com-
paring the outcomes between MIRP and RRP, we included an
additional binary variable indicating whether the patient had
MIRP (MIRP  1) or RRP (MIRP  0).
In addition, we added a subgroup analysis that consisted of
atients with zero comorbidity score. These patients, referred
o as the “healthy subgroup” in the subsequent discussions,
ere chosen to better understand whether the observed differ-
nce between the RRP and MIRP groups may be driven by a
ifference in patients’ case mix. If the difference was indeed
ue to the difference in the case mix between patients in the
RP group and those in the MIRP group, we would expect to find
smaller difference between the two groups in the subgroup
nalysis.
We used SAS 9.2 (SAS Institute Inc., Cary, NC) for datamanage-
ent and STATA 10.1 (StataCorp LP, College Station, TX) for sta-
istical analyses. All P values reported are two-sided; statistical
ignificance is defined as P  0.05.
Results
Our sample included 3144 men treated with MIRP and 7525 men
treated with RRP between 2003 and 2007. The utilization trend of
RPmodalities shows a dramatic increase in MIRP, robotic-assisted
or laparoscopic, increasing from 5.7% of all RPs performed in 2003
to 50.3% in 2007. The comparison of patients’ characteristics (Ta-
ble 2) showed that compared with patients who underwent RRP, a
significantly higher proportion of patients who underwent MIRP
had commercial insurance, but a significantly lower proportion of
them had a comorbidity score of 2 or higher. Table 3 reports find-
ings from the multivariate logistic regression. Similar to the find-
ings from the unadjusted analysis, the adjusted analysis shows no
significant age effect, but significantly higher odds of receiving
ultivariate logistic regressions.
l sample Comorbidity score  0
95% CI Adjusted OR 95% CI
0.86 1.16 1.04 0.88 1.23
0.84 1.07 0.98 0.86 1.12
0.81 1.04 0.92 0.81 1.05
1.03 1.68 1.33 1.01 1.76
1.15 1.71 1.46 1.17 1.83
1.11 1.73 1.44 1.13 1.84
1.15 1.75 1.49 1.18 1.88
1.23 2.44 1.75 1.20 2.54
0.78 1.01 — — —
0.20 0.35 — — —
0.42 0.73 0.51 0.38 0.70
2.20 3.65 2.95 2.24 3.89
4.78 7.75 6.20 4.75 8.08
9.65 15.52 12.87 9.91 16.70
13.26 21.58 17.17 13.14 22.44
0.117 0.111
R, odds ratio; PPO, preferred provider organization.m m
Ful
ORMIRP for patients with commercial insurance. It should be noted,
a
c
371V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 6 7 – 3 7 5however, that although the difference observed between patients
who had commercial insurance versus other types of payers was
not statistically significant, it did not imply that the differencewas
clinically significant.
Compared with patients with indemnity plans, those in HMO,
point of service, and preferred provider organization plans had
1.40 (95% CI 1.15–1.71), 1.38 (1.11–1.73), and 1.42 (1.15–1.75) times
higher odds of receiving MIRP in the full sample and the OR was
1.46 (1.17–1.83), 1.44 (1.13–1.84), and 1.49 (1.18–1.88), respectively,
in the analysis of the healthy subgroup. We chose the indemnity
plans as the reference group in the regression analyses because
compared with other types of health plans, indemnity plans were
least restrictive in patients’ selection of providers and self-refer-
rals. Compared with patients whose comorbidity score was zero,
Table 4 – Perioperative complications, unadjusted.
Perioperative
complications
Full sample
RRP (n  7525) MIRP (n  31
Complications within 90 d of
radical prostatectomy
Cardiac 1.3% 1.2%
Respiratory 5.4% 4.0%
Vascular 2.3% 1.9%
Wound or bleeding 2.1% 1.9%
Genitourinary 4.3% 3.8%
Miscellaneous medical 8.2% 6.0%
Miscellaneous surgical 5.8% 5.1%
Overall (90 d) 30.2% 23.0%
Length of stay 3.1 (SD 2.6) 1.7 (SD 1.7
MIRP, minimally invasive radical prostatectomy; RRP, retropubic rad
* P value for median time to stricture was based on log-rank test an
Pearson’s chi-square test.
Median time to stricture: 99 (RRP) vs. 132 (MIRP) days
0.
00
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00
0 50 100 150 200 250 300 350
Days since Surgery
RRP MIRP
A. Kaplan-Meier Curves of Strictures, Full Sample
Fig. 1 – Kaplan–Meier curve of time to anastomotic strcitures
retropubic radical prostatectomy (RRP): (A) full sample and (B) sathe odds of receivingMIRPwere significantly lower (OR 0.27; 95%CI
0.20–0.35) for those whose comorbidity score was 2 or higher.
The comparison of perioperative complications (Table 4)
shows that the unadjusted overall complication rate was signifi-
cantly higher among patients treated with RRP (30.2% vs. 23.0%;
P  0.001). Compared with the RRP group, the MIRP group had
significantly lower rates of respiratory (4.0% vs. 5.4%; P  0.003)
andmiscellaneousmedical complications (6.0% vs. 8.2%; P 0.01).
Similar conclusionswere found in the healthy subgroup. The com-
parison of Kaplan–Meier curves (see Fig. 1A,B) for stricture shows
that the overall distribution of the MIRP group was significantly
different from that of the RRP group (P  0.0004 in the full sample
nd P  0.001 in the subgroup). Consequently, the overall compli-
ation rate within 3 months of RP was significantly higher for pa-
Comorbidity score  0
P value RRP (n  5968) MIRP (n  2668) P value*
0.68 0.9% 0.8% 0.69
0.003 4.6% 3.7% 0.05
0.21 2.1% 1.6% 0.11
0.45 1.9% 1.9% 0.91
0.20 3.7% 3.6% 0.69
0.001 7.6% 5.7% 0.002
0.15 5.4% 4.9% 0.38
0.001 28.7% 22.2% 0.001
0.001 2.9 (SD 2.0) 1.6 (SD 1.5) 0.001
rostatectomy.
length of stay was based on t test; all other P values were based on
Median time to stricture: 97 (RRP) vs. 148 (MIRP) days
0.
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B. Kaplan-Meier Curves of Strictures, Healthy Subgroup
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372 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 6 7 – 3 7 5tients treated with RRP (30.2% vs. 23. 0%; P  0.001). The adjusted
nalyses from logistic regressions or proportional hazard models
ielded similar conclusions (see Fig. 2A,B). After controlling for pa-
ient age, comorbidity score, payer type, plan type, and time, results
rom logistic regression show that patients in the MIRP group had
ignificantly lower odds of perioperative complications (OR 0.73; 95%
I 0.66–0.81), especially because ofmiscellaneousmedical complica-
ions (OR 0.74; 95% CI 0.62–0.89). Similar findings were observed in the
nalysis of the healthy subgroup. Results from the Cox proportional
azardmodel followingpatientsupto12monthsafterRPshowthat the
IRP grouphad a significantly lower hazard ratio (HR) of stricture, both
n the full sample (HR 0.42; 95% CI 0.35–0.50) and in the subgroup (HR
.42; 95%CI 0.34–0.51).
Table 5 summarizes the difference in costs between patients in
he RRP and MIRP groups. On average, the costs of hospitalization
or RRP and MIRP were $18,424 and $19,998, respectively, whereas
he 6-month cumulative costs were $21,914 and $22,837, respec-
ively. Costs associated with hospitalization for RP was signifi-
antly higher for theMIRP group ($1574 in unadjusted analysis and
833 in adjusted analysis), despite a shorter length of stay reported
or MIRP-related hospitalizations (3.1 days vs. 1.7 days; P  0.001).
he difference in cost between these two modalities diminished
fter a longer follow-up, from a difference of $1215 ($512–$1920)
$970; $214–$1727 in adjusted analysis) in the 3-month cumulative
ost to $923 ($158–$1993) ($8; $952–$969 in adjusted analysis)
n the 6-month cost, whereas the costs of complications were sig-
ificantly higher for the RRP group in both unadjusted ($465; $55–
A. Adjusted Odds Ratio or Hazard Ratio of Perioer
B. Adjusted Odds Ratio or Hazard Ratio of Perioera
0.73 1.14 0.84 0.87
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Fig. 2 – Adjusted odds ratio or hazard ratio of perioperative
with comorbidity score 0. Asterisk denotes hazard ratio from
regression models, and Cox proportional hazard models inc
MIRP (vs. RRP), age groups, payer type, plan types, comorbid
represent the 95% confidence intervals. genit, genitourinary
miscellaneous medical perioperative complications; miscsu
overall_90days, overall perioperative complications within 9
retropubic radical prostatectomy; wound, wound or bleedin805) and adjusted ($432; $130–$733) analyses.Discussion
MIRP, in the form of either robotic-assisted or laparoscopic proce-
dures, is the surgicalmodality preferred bymanypatients because of
the perceived benefit of smaller incisions, shorter hospital stays,
quicker convalescence, and less use of postoperative analgesics
[15,16]. The increasing popularity of MIRP has inspiredmany studies
to use data from a single institution to compare clinical outcomes or
costs betweenMIRP and RRP [16–19]. Before this study, the only pop-
ulation-based studies to examine the trend and compare patient
characteristics and outcomes between these two modalities either
focused exclusively on Medicare beneficiaries (65 years of age and
older) [4,20] or included a mix of young and old patients [5,6]. Our
study is the first population-based study to evaluate utilization and
outcomes, andmore important, to provide cost estimates of RRP ver-
sus MIRP, among young patients with prostate cancer.
Prostate cancer diagnosis in nonelderly men has increased dra-
matically since the introduction of prostate-specific antigen screen-
ing [21]. By using the Surveillance, Epidemiology, and End Results
(SEER) data,Welch andAlbertsen demonstrated distinct age-specific
trends with little net change in diagnosis for men in their sixth and
seventh decades of life, but a tripling of prostate cancer diagnosis
among men of age 50 to 59 years (58.4–212.7 per 100,000; risk ratio
[RR] 3.64) and amore than sevenfold increase among those younger
than 50 years (1.3–9.4 per 100,000; RR 7.23) [21]. The age groups expe-
riencing the dramatic increase in prostate cancer diagnosis are also
the focus of this study.
A comparison of our findings and those from a recently pub-
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373V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 6 7 – 3 7 5terns. First, the rising utilization of MIRP observed among the el-
derly patients was also found among younger patients. Hu et al.
reported an increase in the utilization of MIRP from 9.2% in 2003 to
30.9% in 2005 and then to 43.2% in 2006–2007 among Medicare
beneficiaries who received RP and resided in the SEER regions. In
comparison, we documented increases in the utilization of MIRP
from 5.7% in 2003 to 26.9% in 2005 and then to 50.3% in 2007.
Despite a higher rate of an initial uptake of MIRP among elderly
patients with prostate cancer, MIRP became more widely diffused
among younger patients between 2005 and 2007.
Second, both studies found that MIRP was associated with
fewer perioperative complications and shorter hospitalizations
than was RRP. These findings are in line with historical data on
RRP and more recent studies that have reported a lower rate of
strictures [22,23] and shorter hospitalizations [15,17,19,24,25] with
he minimally invasive approach. Hu et al. did not conduct a for-
al cost analysis, although in one of their earlier studies using
edicare data [4], they hypothesized that the shorter hospitaliza-
ions and lower transfusion rates associated withMIRPmay result
n a cost advantage for that modality. This hypothesis was not
upported by our cost analysis. Our finding of higher hospitaliza-
ion cost of MIRP is consistent with other published cost studies
15,18,19,24,25]. Both Lotan et al. [25] and Anderson et al. [15] con-
cluded that the higher cost of MIRP was primarily driven by higher
equipment costs and longer operative time associated with this
procedure. A unique contribution of our study is to provide an
estimate of the costs of perioperative complications. We found
that on average the complication costs per patientweremore than
$400 higher in the RRP group; this finding was consistent with the
higher rate of overall complications reported earlier and explained
the reduction in the difference in the 6-month cost between
groups.
Themost striking difference between the study byHu et al. and
our study is that we found that a significantly smaller proportion
of the MIRP group had multiple comorbid conditions while no sig-
nificant association was found in their study. In an exploratory
analysis, we compared the comorbidity scores for patients who
underwent RP before and after 2003, patients who underwent RRP
before and after 2003, and patients who underwent MIRP and RRP
after 2003 (as MIRP was not available before 2003). We found a
significant reduction in the average score among patients who
underwent RP over time (0.35 vs. 0.29; P 0.001), but no significant
difference among the RRP group over time (0.35 vs. 0.34; P  0.69).
e also found a significantly lower average score in the MIRP
roup (0.19 in MIRP vs. 0.34 in RRP; P  0.001) after 2003, which
uggested that the lower average score observed among the RP
roup after 2003 was mostly driven by the MIRP group. This anal-
sis, combined with our finding of a lower OR of MIRP among
atients with higher comorbidity scores and a trend toward an
Table 5 – Comparison of costs between patients treated wi
Mean
RRP MIR
Length of stay (d) 3.1
Costs of RP hospitalization ($) 18,424 19,99
Within 3 mo of RP ($) 21,183 22,39
Within 6 mo of RP
Total costs ($) 21,914 22,83
Costs of complications ($) 1231 76
CI, confidence interval; MIRP, minimally invasive radical prostatecto
* CIs obtained from the nonparametric bootstrapping method.
† CIs obtained from the extended estimation equation method.ncreasing number of RPs but a decreasing number of RRPs from h004 to 2006 (Table 1), suggests that the uptake of MIRP did not
ccur by simply replacing the existing technology (RRP) but was
ore likely driven by an increasing use of MIRP among a group of
atients who were not previously inclined to undergo surgery for
rostate cancer. The above observation is consistent with that
rom a number of studies in the literature in which a concern
egarding the overtreatment of localized prostate cancer has been
xpressed [26–28]. The possibility that increased utilization of
IRP represents the overtreatment of prostate cancer is an impor-
ant topic for future research.
Theaboveobservationalso raised a concern that the lower rate of
omplications found in theMIRP groupmay be driven by a favorable
election into MIRP; that is, those otherwise healthy young patients
ould choose MIRP over RRP once they decided to undergo surgery.
he choice of MIRP over RRP could be driven by patients as well as
heir surgeons. We dealt with this issue by controlling for the use of
djuvant radiation in themultivariate analyses and also by adding a
ubgroupanalysis that limited thestudysample topatientswithzero
omorbidity score (i.e., thehealthy subgroup). Results from this anal-
sis, however, were largely similar to those reported from the full
ample. It is possible that the use of adjuvant radiation and comor-
idity score alone are not sufficient to properly address the potential
ias resulting from sample selection. Addressing this concern will
equire the application of the treatment effect model [29]. Such a
odel would require the identification of valid instrumental vari-
bles to address the issue of treatment assignment owing to unob-
erved characteristics. Common choices of instruments include
istance between the patient’s residence and his provider, as well
s variation in supply-side or demand-side factors across geo-
raphic regions. Unfortunately, the lack of geographic information
n the LifeLink Health Plan Claims Database severely limited our
bility to identify valid instrumental variables. Thus, future stud-
es should explore this issue by using population-based data with
ore detailed geographic information.
Nevertheless, the current literature can provide insights to
elp us project the direction of biases driven by treatment selec-
ion. It is important to bemindful of the potential biases as a result
f covariates not collected in our data but had beendocumented as
elated to the use of various forms of RP and the associated out-
omes. Patients with higher tumor stage may require more exten-
ive surgery, which then increases the risk of complications. A
revious study has shown that higher prostate-specific antigen
as associated with a higher rate of anastomotic stricture [30],
lthough conflicting findings have also been reported [31]. In ad-
ition, worse outcomes have been found among minorities or
hose with a more disadvantaged socioeconomic status. Hu et al.
20] showed that tumor stage was higher for the RRP group and
hat the use of MIRP was less likely to be reported among minori-
ies and patients residing in low-socioeconomic-status neighbor-
P vs. MIRP.
Cost difference (RRP – MIRP)
Unadjusted*
[95% CI]
Adjusted†
[95% CI]
1.4 [1.3 to 1.5] 1.2 [1.1 to 1.3]
1574 [2144 to 1015] 833 [1394 to 272]
1215 [1920 to 512] 970 [1727 to 214]
$923 [1993 to 158] $8 [952 to 969]
465 [55 to 805] 432 [130 to 733]
P, radical prostatectomy; RRP, retropubic radical prostatectomy.th RR
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possible that the higher rate of complications in the RRP group was
driven by the difference in clinical, racial, and socioeconomic com-
positions between the two groups. It is difficult to project the impact
of the lack of surgical volume variable on outcomes because the vol-
ume–outcome relationship remained inconclusive. Although better
outcomes have been observed among patients treated by high-vol-
ume surgeons [32,33], a recent study also reported that surgeon vol-
ume did not explain the difference in outcomes between RRP and
MIRP [20]. It should be noted that despite their use of the propensity
score method to balance the observed characteristics between the
MIRP and RRP groups, Hu et al. [20] reported that findings from their
adjusted analyses were similar to those from unadjusted analyses;
therefore, it is possible that our findingmaypersist hadwe been able
to control for the above covariates in our analyses.
The database used in our analysis allows better investigation of
the association between insurance characteristics and the use of
MIRP. The LifeLink Health Plan Claims Database collected infor-
mation on payer type and health plan type. By dichotomizing the
payer categories into commercial versus noncommercial payers,
we were able to compare payers who are likely to have more gen-
erous insurance coverage versus those with less generous cover-
age as the noncommercial payers consisted of patients who were
self-insured, held public insurance, or had unknown payer type.
Therefore, if the purchase of costly capital equipment such as a
robotic system would provide a financial incentive for physicians
to promote robotic-assisted MIRP, patients with more generous
insurance coverage were likely to be more attractive candidates.
Thismight explain our finding of a higher OR associatedwith com-
mercial plans. The variable of health plan type captures different
degrees of restrictions that insurance plans placed on the selec-
tion of providers, with the indemnity plan being the least restric-
tive type. The higher odds of MIRP observed among patients in
plans that are more restrictive than those in the indemnity plans
could be an indication that the use of MIRP is more likely to be
driven by physicians, rather than patients. If MIRP was patient
driven, we would have observed lower odds of MIRP among pa-
tients in more restrictive plans because patients in the indemnity
plans would have less barriers to seek out physicians who will
perform MIRP.
In addition to the issue of favorable selection discussed above,
this study has several other limitations. First, claims databases often
lack detailed clinical information because they are generated for bill-
ing purposes. Althoughwewere able to document a growing utiliza-
tion of MIRP among nonelderly patients with lower comorbidity, we
were not able to conclude definitively whether the majority of the
increase was driven by patients with low-risk tumors. Second, we
were not able to differentiate between laparoscopic RP performed
with and without robotic assistance because both procedures share
the sameCPT code. Therefore, our studywasnot able to examine the
extent to which the growing use of MIRP was associated with the
recent expansion of robotic systems [28,34]. We plan to answer
these questions whenmore recent data become available because a
new ICD-9 procedure code (17.42) was added for a laparoscopic ro-
botic-assisted procedure in October 2008.
Third, for the less common perioperative complication, our sam-
ple may not have sufficient power to detect the difference between
the MIRP and RRP groups. This concern is especially relevant to the
analysis of cardiac, vascular, and wound/bleeding complication
among the healthy subgroup. Lastly, because of the proprietary na-
ture of the LifeLink Health Plan Claims Database, neither provider
identifier nor geographic information was available. Thus, we were
not able toexamine the impactof surgeonvolumesonoutcomes,nor
were we able to account for the clustering effect of providers. Find-
ings on geographic variations among elderly patients with RP were
not consistent in the literature. A study based on Medicare claims
data foundnogeographic variation in theutilizationof RRP andMIRP[4], whereas another study using SEER-Medicare data reported a
higher rate ofMIRP in SEER regionswithhigh-volumeRP centers [20].
t is not clear whether a similar trend would persist among non-
lderly patients with prostate cancer.
Despite these limitations, our studymakes a unique contribution
o the literature. It is the first population-based study of the utiliza-
ion and cost of RP modalities exclusively among nonelderly men.
hus, our study offers an opportunity to contrast the pattern ob-
erved among elderly and nonelderly patients. More important, the
bservation of the increasing use ofMIRP amongnonelderly patients
ith lower comorbidity suggests various forces at play. This may
nclude the conversion of patients from active surveillance or from
ther nonsurgicalmodalities toMIRP, direct-to-consumer advertise-
ent frommanufacturers, or a combination of all these.
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